1. Federal Register (1996). International conference on harmonisation; fmal guidelines on stability testing of biotechnological/ biological products; availability; notice. 61,36466–36469.
2. Nguyen, T.H. and Shire, S.J. (1996). Stability and characterization of recombinant human relaxin. In: Pearlman, R. and Wang, Y.J. (Eds.) Formulation, characterization and stability of protein drugs. Plenum. New York.
3. Hora, M.S. et al. (1992). Lyophilized formulations of recombinant tumor necrosis factor. Pharm. Res., 9, 33–36.
4. Shire, S.J. Stability, characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme® (dornase alpha)] In: Pearlman, R. and Wang, Y.J. (Eds.) Formulation, characterization and stability of protein drugs. Plenum. New York.
5. Wang, Y.-C. J. and Hanson. M. A. (1988). Parenteral Formulations of proteins and peptides: stability and stabilisers. J. Parenteral Sci. & Tech. 42, S4–S26.